Results 171 to 180 of about 150,778 (261)

A major histocompatibility complex (MHC) class II molecule that binds the same viral pathogen peptide with both nonamer and decamer core sequences for presentation to T cells. [PDF]

J Virol
Goryanin A, Cook AG, Behboudi S, Kaufman J, Halabi S.   +4 more
europepmc   +1 more source

MicroRNAs as potential architects of immune dysregulation and megakaryocytic failure in immune thrombocytopenia

British Journal of Haematology, EarlyView.
Summary Immune thrombocytopenia (ITP) is a complex autoimmune disorder characterized by accelerated destruction of peripheral platelets and impaired megakaryopoiesis. While the cellular effectors, dysregulated T cells, hyperactive B cells and phagocytic macrophages are well characterized, the upstream epigenetic mechanisms orchestrating this ...
Zhenyu Liu, Johan Rebetz, Lamya Garabet, Waleed Ghanima, Peipei Xu, Hans Wadenvik, Drew Provan, Rick Kapur, John W. Semple   +8 more
wiley   +1 more source

Status quo of histocompatibility testing and prospects for virtual crossmatching within the Korean kidney allocation system: survey of laboratory directors. [PDF]

Clin Transplant Res
Yang JJ, Park BG, Choi HW, Song EY, Yang J, Park JB, Kang ES.   +6 more
europepmc   +1 more source

Oligoprogressive renal cell carcinoma: What is the role of surgery?

BJU International, EarlyView.
Objective To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and
Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart   +9 more
wiley   +1 more source

Targeting intratumoral bacteria reverses MHC-I suppression and enhances nano-based chemoimmunotherapy in colorectal cancer. [PDF]

Mil Med Res
Feng J, Liu YH, Gong LM, Zhang WX, Liu CF, Xiao CC, Chen LQ, Jin MJ, Guan YY, Gao ZG, Huang W.   +10 more
europepmc   +1 more source

The IPD-IMGT/HLA database: recent developments in sequence submission. [PDF]

Nucleic Acids Res
Barker DJ, Natarajan RHL, Cooper MA, Hopper SJF, Yates AD, Parham P, Marsh SGE, Robinson J.   +7 more
europepmc   +1 more source

Are we hallucinating or can psychedelic drugs modulate the immune system to control inflammation?

British Journal of Pharmacology, EarlyView.
Psychedelic drugs that activate 5‐HT2A receptors have been long used for cultural, medicinal and recreational purposes. Interest in psychedelics for treating psychiatric disorders has resurged recently and is well documented; less well recognised are their anti‐inflammatory properties. Growing evidence now demonstrates that psychedelics modulate immune
Omar Qureshi, Jamie Cowley, Ashley Pegg, Alison J. Cooper, John Gordon, Catherine A. Brady, Antonio Belli, Sam Butterworth, Rachel Upthegrove, Nick Andrews, Nicholas M. Barnes   +10 more
wiley   +1 more source

Rapamycin-modified novel tolerogenic dendritic cells induce liver graft tolerance through MHC-II+CD8+ regulatory T cells. [PDF]

Hepatol Commun
Zhou L, Zhao Y, Wang J, Chen Q, Jia YN, Pan LC, Wang HX, Yang HW, He Q, Li XL, Lang R, Du GS.   +11 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

HLA incompatibility mitigation strategies in off-the-shelf cancer immunotherapies: clinical implications and a practical framework for strategy selection and combination. [PDF]

Front Immunol
Das R, Askar M.
europepmc   +1 more source